Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.
References
[1]
Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, et al. (2012) No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial. PLoS Med 9 ((3)) e1001196. doi: 10.1371/journal.pmed.1001196
[2]
Hogan CM, Degruttola V, Sun X, Fiscus SA, Del RC, et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205: 87–96. doi: 10.1093/infdis/jir699
[3]
Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. (2013) Short-Course Antiretroviral Therapy in Primary HIV Infection. N Engl J Med 368: 207–217. doi: 10.1056/nejmoa1110039
[4]
Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, et al. (2002) Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 16: 2049–2054. doi: 10.1097/00002030-200210180-00010
[5]
Taylor S, Boffito M, Khoo S, Smit E, Back D (2007) Stopping antiretroviral therapy. AIDS 21: 1673–1682. doi: 10.1097/qad.0b013e3281c61394
[6]
Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356: 135–147. doi: 10.1056/nejmoa062876
[7]
Jourdain G, Ngo-Giang-Huong N, Le CS, Bowonwatanuwong C, Kantipong P, et al. (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229–240. doi: 10.1056/nejmoa041305
[8]
El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283–2296. doi: 10.1056/nejmoa062360
[9]
Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22: 2279–2289. doi: 10.1097/qad.0b013e328311d16f
[10]
Viread (tenofovir). (2006) Summary of procuct characteristics. Gilead Sciences International Limited. Cambridge, UK.
[11]
Taylor S, Jayasuriya A, Fisher M, Allan S, Wilkins E, et al. (2012) Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. J Antimicrob Chemother 67: 675–680. doi: 10.1093/jac/dkr491
